发明名称 |
COMBINATION THERAPY |
摘要 |
A pharmaceutical combination comprising (a) a compound of formula (I),;;or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering. |
申请公布号 |
US2016287605(A1) |
申请公布日期 |
2016.10.06 |
申请号 |
US201615184399 |
申请日期 |
2016.06.16 |
申请人 |
Sheng Qing;Wang Hui-Qin;Li Fang;Liang Jinsheng;Cao Zhu Alexander;Monahan John;Versace Richard |
发明人 |
Sheng Qing;Wang Hui-Qin;Li Fang;Liang Jinsheng;Cao Zhu Alexander;Monahan John;Versace Richard |
分类号 |
A61K31/5377;A61K31/506 |
主分类号 |
A61K31/5377 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pharmaceutical combination comprising:
(a) compound having Formula:and
(b) 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or pharmaceutically acceptable salt thereof. |
地址 |
Sharon MA US |